Tissue penetration of antimicrobials: Difference between revisions

From IDWiki
No edit summary
No edit summary
Line 5: Line 5:
!Blood
!Blood
!CNS
!CNS
!Vitreous
!Urine
!Urine
!Prostate
!Prostate
!Necrotic
!Necrotic
|-
|-
! colspan="7" |Antibiotics: β-Lactams
! colspan="8" |Antibiotics: β-Lactams
|-
|-
| rowspan="3" |[[Penicillins]]
| rowspan="3" |[[Penicillins]]
Line 15: Line 16:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 22: Line 24:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 29: Line 32:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +†
| style="text-align:center" | +†
Line 37: Line 41:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 44: Line 49:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 51: Line 57:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +†
| style="text-align:center" | +†
Line 58: Line 65:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 65: Line 73:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 73: Line 82:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 80: Line 90:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 88: Line 99:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
|-
|-
! colspan="7" |Antibiotics: Non-β-Lactams
! colspan="8" |Antibiotics: Non-β-Lactams
|-
|-
|[[Aminoglycosides]]
|[[Aminoglycosides]]
Line 98: Line 110:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 106: Line 119:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 114: Line 128:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–?
| style="text-align:center" |–?
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
Line 122: Line 137:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
Line 130: Line 146:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 138: Line 155:
| +
| +
|–
|–
|
| +
| +
|
|
Line 146: Line 164:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
Line 154: Line 173:
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |–
|
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" |–
| style="text-align:center" |–
Line 162: Line 182:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 170: Line 191:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
Line 178: Line 200:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
Line 186: Line 209:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
Line 193: Line 217:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" | +
|-
|-
! colspan="7" |Antifungals
! colspan="8" |Antivirals
|-
|
|[[acyclovir]] / [[valacyclovir]]
|
|
| +
|
|
|
|-
|
|[[ganciclovir]]
|
|
| +
|
|
|
|-
|
|[[foscarnet]]
|
|
|
|
|
|
|-
! colspan="8" |Antifungals
|-
|-
|[[Azoles]]
|[[Azoles]]
Line 203: Line 257:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 211: Line 266:
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |
| style="text-align:center" |
Line 219: Line 275:
!Blood
!Blood
!CNS
!CNS
!
!Urine
!Urine
!Prostate
!Prostate

Revision as of 17:11, 13 February 2021

Summary

Class Antimicrobial Blood CNS Vitreous Urine Prostate Necrotic
Antibiotics: β-Lactams
Penicillins β-lactamase inhibitors
ampicillin +
piperacillin-tazobactam +†
Cephalosporins first-generation cephalosporins
second-generation cephalosporins
third-generation cephalosporins +†
cefepime +
ceftazidime + +
Cephamycins cephamycins
cefoxitin
Carbapenems imipenem +
Antibiotics: Non-β-Lactams
Aminoglycosides
Chloramphenicol chloramphenicol +
Fluoroquinolones –? + +
Fosfomycin fosfomycin +
Lincosamides clindamycin +
Lipopeptides daptomycin + +
Macrolides macrolides +
Nitrofurans nitrofurantoin +
Nitroimidazoles metronidazole +
Rifamycins rifampin +
Sulfonamides trimethoprim-sulfamethoxazole +
Tetracyclines tetracyclines +
doxycycline + +
Antivirals
acyclovir / valacyclovir +
ganciclovir +
foscarnet
Antifungals
Azoles fluconazole +
Echinocandins +
Class Antimicrobial Blood CNS Urine Prostate Necrotic
  • † if inflammation present

Prostate

  • Poorly penetrated by most antibiotics
  • Penetration is higher with a high concentration gradient, high lipid solubility, low degree of ionization, high dissociation constant, low protein binding, and small molecular size
  • Fluoroquinolones are the mainstay of therapy, though there is increasing resistance
  • TMP-SMX often used, though conflicting data about its penetration into the prostate
  • Minocycline, doxycycline, and macrolides achieve high levels in the prostate but are rarely indicated for the causative organisms
  • Third-generation cephalosporins and carbapenems can be used
  • Piperacillin, aztreonam, imipenem, and some aminoglycosides are likely useful

Bone

  • Essentially all antibiotics achieve similar bone-to-serum levels, with the exception of oral β-lactams which nevertheless have no worse outcomes1

References

  1. ^  Cornelia B. Landersdorfer, Jürgen B. Bulitta, Martina Kinzig, Ulrike Holzgrabe, Fritz Sörgel. Penetration of Antibacterials into Bone. Clinical Pharmacokinetics. 2009;48(2):89-124. doi:10.2165/00003088-200948020-00002.
  2. a b c d e f g h i j k l m n o p q r  L. Brockhaus, D. Goldblum, L. Eggenschwiler, S. Zimmerli, C. Marzolini. Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics. Clinical Microbiology and Infection. 2019;25(11):1364-1369. doi:10.1016/j.cmi.2019.01.017.
  3. a b  Takashi Suzuki, Toshihiko Uno, Guangming Chen, Yuichi Ohashi. Ocular distribution of intravenously administered micafungin in rabbits. Journal of Infection and Chemotherapy. 2008;14(3):204-207. doi:10.1007/s10156-008-0612-5.
  4. a b c d e f g h  Timothy Felton, Peter F. Troke, William W. Hope. Tissue Penetration of Antifungal Agents. Clinical Microbiology Reviews. 2014;27(1):68-88. doi:10.1128/cmr.00046-13.